Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Oncolytics Biotech Inc.    ONC   CA6823108759

ONCOLYTICS BIOTECH INC. (ONC)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
09/13/2018 09/14/2018 09/17/2018 09/18/2018 09/19/2018 Date
5.77(c) 6.48(c) 5.86(c) 5.7(c) 5.71 Last
59 156 66 340 101 749 33 010 22 700 Volume
+8.26% +12.31% -9.57% -2.73% +0.18% Change
More quotes
Financials (CAD)
Sales 2018 0,50 M
EBIT 2018 -
Net income 2018 -20,4 M
Debt 2018 -
Yield 2018 -
Sales 2019 3,50 M
EBIT 2019 -
Net income 2019 -21,4 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 188x
Capi. / Sales2019 26,9x
Capitalization 94,2 M
More Financials
Company
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies.It offers a non-pathogenic, properietary isolate of the reovirus called REOLYSIN.The company was founded by Matthew C. Coffey and Bradley George Thompson on... 
More about the company
Surperformance© ratings of Oncolytics Biotech Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on ONCOLYTICS BIOTECH INC.
09/10Today's Research Reports on Aralez Pharmaceuticals, OrganiGram Holdings, Onco..
AC
08/10Today's Research Reports on Emblem, OrganiGram Holdings, Oncolytics Biotech a..
AC
08/03Oncolytics Biotech® Reports 2018 Second Quarter Results
GL
07/18Today's Free Reports Concordia International ProMetic Life Sciences Oncolytic..
AC
07/11Today's Research Reports on Emblem, OrganiGram, Oncolytics Biotech and Aptose..
AC
06/20Today's Free Reports Concordia International, ProMetic Life Sciences, Aurinia..
AC
06/05Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares
GL
06/04ONCOLYTICS BIOTECH : reg; Announces Poster Presentation Demonstrating the Abilit..
PU
06/01ONCOLYTICS BIOTECH : Announces Public Offering of Common Shares
AQ
05/31Oncolytics Biotech® Announces Public Offering of Common Shares
GL
More news
Sector news : Biotechnology & Medical Research - NEC
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans -- U..
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/12EUROPE : European stocks shrug off trade worries as oil stocks rally
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/17Oncolytics Biotech announces multiple myeloma study combining REOLYSIN and ni.. 
09/17Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study C.. 
09/14MOST ACTIVE ALERT: $ONCY ONCOLYTICS BIOTECH ? TradeIdeas via  
09/10Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunit.. 
09/10Oncolytics Biotech collaborates with SOLTI to conduct a window of opportunity.. 
More tweets
Qtime:11
News from SeekingAlpha
08/03Oncolytics Biotech reports Q2 results 
07/11ONCOLYTICS : Significant Pipeline Value In The Fastest Growing Area Of Oncology. 
07/01WEEK IN REVIEW : CStone Acquires China Rights To Leukemia Drug In $424 Million D.. 
06/11FUTURE DIRECTIONS FOR ONCOLYTICS :   Partnerships + Buyouts 
Chart ONCOLYTICS BIOTECH INC.
Duration : Period :
Oncolytics Biotech Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCOLYTICS BIOTECH INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,2  CAD
Spread / Average Target 289%
EPS Revisions
Managers
NameTitle
Matthew C. Coffey President, CEO, COO & Director
Wayne F. Pisano Chairman
Kirk J. Look Chief Financial Officer
J. Mark Lievonen Independent Director
Angela Holtham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ONCOLYTICS BIOTECH INC.-13.12%74
CELLTRION, INC.--.--%33 722
IQVIA HOLDINGS INC28.24%25 338
LONZA GROUP20.74%24 487
INCYTE CORPORATION-29.24%14 247
SEATTLE GENETICS, INC.45.25%12 094